Fd

Funding

Funding is a core element of ERDERA’s strategy to transform rare disease research in Europe. Its mission is to bridge gaps in scientific knowledge, foster international collaborations, and deliver tangible benefits to millions of patients affected by rare diseases across Europe and beyond.

ERDERA Funding

By pooling resources from the regional/national funding agencies, the EC, the private sector organisations, and philanthropic foundations, ERDERA drives forward groundbreaking research that has the potential to transform lives.

ERDERA’s funding research strategy is built upon a diversity of calls: Joint Transnational Calls, Clinical Trials Calls and the Networking Support Scheme. The topics of these calls will be selected by gap analysis according to the needs of the rare disease community gathered from the recommendations of the ERDERA’s advisory and governing bodies.

icon-joint-transnational-call

Joint Transnational Calls

Supports interdisciplinary research to address identified gaps. These calls foster cross-border collaboration and align with the strategic priorities of the rare disease community.

icon-clinical-trias-call

Clinical Trials Call

Funds controlled clinical research studies undertaken in humans to establish or confirm the safety and effectiveness of therapeutic interventions. These will benefit from ERDERA support for regulatory and methodological aspects.

icon-networking-support-scheme

The Networking Support Scheme

Plays a crucial role in building the research ecosystem by fostering knowledge sharing across national and international actors, attracting underrepresented regions, engaging young researchers, and strengthening the involvement of patient organisations.

Active & Upcoming Calls

icon-joint-transnational-call

Joint Transnational Call 2025

icon-networking-support-scheme

Networking Support Scheme (NSS)

erdera’s funding projects AND EVENTS

Last Activities

icon-networking-support-scheme

CureDravet2

The gene therapy pipeline is intransigently linked to vector efficacy. Due to a paucity of vectors capable of harboring large expression cassettes, several rare diseases have little hope of being targets
icon-joint-transnational-call

CureDravet

The gene therapy pipeline is intransigently linked to vector efficacy. Due to a paucity of vectors capable of harboring large expression cassettes, several rare diseases have little hope of being targets

ERDERA FUNDING

You might also be interested in

EJP RD Final Conference

Training for Resources joining the Rare Diseases Virtual Platform

Item media test 2

Discussions delved into targeted newborn screening programs, advanced clinical trials, and innovative translational reçsearch platforms.

ERDERA’s Networking Support Scheme opens to forge new rare disease and rare cancer alliances